Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
canagliflozin (380) 380
humans (363) 363
index medicus (328) 328
diabetes mellitus, type 2 - drug therapy (305) 305
type 2 diabetes (214) 214
diabetes (208) 208
hypoglycemic agents - therapeutic use (207) 207
hypoglycemic agents - adverse effects (199) 199
male (197) 197
female (193) 193
glucose (176) 176
middle aged (169) 169
sodium-glucose transporter 2 - antagonists & inhibitors (163) 163
dapagliflozin (160) 160
endocrinology & metabolism (155) 155
double-blind (146) 146
safety (138) 138
aged (127) 127
glucosides - therapeutic use (123) 123
canagliflozin - therapeutic use (121) 121
type 2 diabetes mellitus (115) 115
canagliflozin - adverse effects (113) 113
glucosides - adverse effects (112) 112
empagliflozin (109) 109
adult (106) 106
efficacy (105) 105
metformin (105) 105
diabetes mellitus, type 2 - blood (103) 103
diabetes mellitus (99) 99
treatment outcome (99) 99
glycemic control (97) 97
medicine, general & internal (96) 96
hypoglycemic agents - administration & dosage (95) 95
pharmacology & pharmacy (91) 91
double-blind method (86) 86
insulin (86) 86
sglt2 inhibitor (86) 86
blood glucose - drug effects (85) 85
dextrose (85) 85
mellitus (82) 82
blood pressure (78) 78
thiophenes - therapeutic use (74) 74
blood glucose - metabolism (72) 72
sodium (72) 72
drug therapy (71) 71
care and treatment (70) 70
body weight (68) 68
thiophenes - adverse effects (67) 67
clinical trials (65) 65
monotherapy (64) 64
sglt2 inhibitors (63) 63
benzhydryl compounds - therapeutic use (62) 62
inadequate glycemic control (62) 62
hypoglycemic agents - pharmacology (57) 57
sitagliptin (57) 57
drug therapy, combination (55) 55
glucosides - administration & dosage (54) 54
glycated hemoglobin a - metabolism (54) 54
add-on (53) 53
analysis (53) 53
benzhydryl compounds - adverse effects (53) 53
dose-response relationship, drug (53) 53
hypoglycemic agents (51) 51
internal medicine (50) 50
sodium-glucose transporter 2 - metabolism (50) 50
blood pressure - drug effects (49) 49
diabetes therapy (49) 49
hypoglycemia (49) 49
hyperglycemia (48) 48
sglt2 (48) 48
canagliflozin - administration & dosage (47) 47
hemoglobin (46) 46
hypoglycemia - chemically induced (44) 44
risk factors (44) 44
diabetes mellitus, type 2 - complications (43) 43
glucosides - pharmacology (43) 43
patients (43) 43
abridged index medicus (42) 42
diabetes mellitus, type 2 - metabolism (42) 42
inhibitor (42) 42
randomized controlled trials as topic (42) 42
glucose cotransporter 2 (41) 41
medicine, research & experimental (40) 40
long-term efficacy (39) 39
placebo (39) 39
thiophenes - administration & dosage (39) 39
type-2 diabetes-mellitus (39) 39
body weight - drug effects (38) 38
research (37) 37
sulfonylurea (37) 37
diabetes mellitus, type 2 - physiopathology (36) 36
glycosylated hemoglobin (36) 36
mortality (36) 36
young adult (36) 36
cardiovascular disease (35) 35
complications and side effects (35) 35
metformin - therapeutic use (35) 35
studies (35) 35
body mass index (33) 33
endocrinology (33) 33
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Canagliflozin mediated dual inhibition of mitochondrial glutamate dehydrogenase and complex I: an off-target adverse effect
by Secker, PF and Beneke, S and Schlichenmaier, N and Delp, J and Gutbier, S and Leist, M and Dietrich, DR
CELL DEATH & DISEASE, ISSN 2041-4889, 02/2018, Volume 9, Issue 2, pp. 226 - 13
Recent FDA Drug Safety Communications report an increased risk for acute kidney injury in patients treated with the gliflozin class of sodium/glucose... 
BIOCHEMICAL ASSAYS | GLUCOSE COTRANSPORTER 2 | TCA CYCLE | AEROBIC GLYCOLYSIS | KIDNEY INJURY | CELL-PROLIFERATION | TYPE-2 DIABETES-MELLITUS | PROXIMAL TUBULE | CHRONIC SAFETY | ELECTRON-TRANSPORT | CELL BIOLOGY | Mitochondria - enzymology | Epithelial Cells - drug effects | Humans | Glutamine - metabolism | Electron Transport Complex I - metabolism | Glutamate Dehydrogenase - antagonists & inhibitors | Cell Death - drug effects | Kidney Tubules, Proximal - enzymology | Epithelial Cells - cytology | Glutamate Dehydrogenase - metabolism | Cell Line | Kidney Tubules, Proximal - cytology | Glucosides - pharmacology | Electron Transport Complex I - antagonists & inhibitors | Citric Acid Cycle - drug effects | Alanine - metabolism | Canagliflozin - adverse effects | Mitochondria - drug effects | Glucosides - metabolism | Metabolomics - methods | Epithelial Cells - enzymology | Benzhydryl Compounds - pharmacology | Glutamic Acid - metabolism | Hypoglycemic Agents - adverse effects | Benzhydryl Compounds - metabolism | Kidney Tubules, Proximal - drug effects | Cell proliferation | Glutamate dehydrogenase | Tricarboxylic acid cycle | Metabolomics | Alanine | Renal function | Kidneys | Dehydrogenases | Epithelial cells | Diabetes mellitus | Cytotoxicity | Amino acids | Glucose transport | Patients | Electron transport chain | Side effects | Mitochondria | Metabolites | Sodium | Cell death | Diabetes mellitus (non-insulin dependent) | Clear cell-type renal cell carcinoma | Glutamine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
by Lavalle-González, F J and Januszewicz, A and Davidson, J and Tong, C and Qiu, R and Canovatchel, W and Meininger, G
Diabetologia, ISSN 0012-186X, 12/2013, Volume 56, Issue 12, pp. 2582 - 2592
The aim of this work was to evaluate the efficacy and safety of canagliflozin vs placebo and sitagliptin in patients with type 2 diabetes who were being... 
Sodium glucose co-transporter 2 (SGLT2) inhibitor | Medicine & Public Health | Human Physiology | Canagliflozin | Metabolic Diseases | Internal Medicine | Sitagliptin | Metformin | Type 2 diabetes mellitus | GLIPIZIDE | ADD-ON | SULFONYLUREA | DAPAGLIFLOZIN | MELLITUS | INADEQUATE GLYCEMIC CONTROL | DIET | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | 52-WEEK | INHIBITOR | Blood Pressure | Triazoles - administration & dosage | Triazoles - adverse effects | Thiophenes - adverse effects | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Pyrazines - administration & dosage | Glycated Hemoglobin A - drug effects | Body Weight - drug effects | Lipids | Male | Thiophenes - administration & dosage | Metformin - adverse effects | Hypoglycemic Agents - administration & dosage | Aged, 80 and over | Female | Metformin - administration & dosage | Sitagliptin Phosphate | Drug Therapy, Combination | Glucosides - adverse effects | Fasting | Treatment Outcome | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Glucosides - administration & dosage | Adolescent | Pyrazines - adverse effects | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Complications and side effects | Care and treatment | Body weight | Glucose | Comparative analysis | Dextrose
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study
by Leiter, Lawrence A and Leiter, Lawrence A and Yoon, Kun-Ho and Yoon, Kun-Ho and Arias, Pablo and Arias, Pablo and Langslet, Gisle and Langslet, Gisle and Xie, John and Xie, John and Balis, Dainius A and Balis, Dainius A and Millington, Dawn and Millington, Dawn and Vercruysse, Frank and Vercruysse, Frank and Canovatchel, William and Canovatchel, William and Meininger, Gary and Meininger, Gary
Diabetes care, ISSN 0149-5992, 03/2015, Volume 38, Issue 3, pp. 355 - 364
To assess the efficacy/safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, compared with glimepiride over 104 weeks in patients with type 2... 
Thiophenes - adverse effects | Humans | Middle Aged | Body Weight - drug effects | Male | Thiophenes - administration & dosage | Metformin - adverse effects | Hypoglycemic Agents - administration & dosage | Time Factors | Female | Sulfonylurea Compounds - administration & dosage | Metformin - administration & dosage | Drug Therapy, Combination | Hypoglycemia - chemically induced | Glucosides - adverse effects | Double-Blind Method | Treatment Outcome | Sulfonylurea Compounds - adverse effects | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Canagliflozin | Glucosides - administration & dosage | Weight Loss | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Care and treatment | Usage | Analysis | Clinical trials | Glycemic index | Dosage and administration | Metformin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
by Watts, Nelson B and Bilezikian, John P and Usiskin, Keith and Edwards, Robert and Desai, Mehul and Law, Gordon and Meininger, Gary
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 01/2016, Volume 101, Issue 1, pp. 157 - 166
Context: Canagliflozin is a sodium glucose cotransporter 2 inhibitor developed to treat type 2 diabetes mellitus (T2DM). Objective: The purpose of this study... 
LONG-TERM | FALLS | GLYCEMIC CONTROL | BONE-MINERAL DENSITY | EFFICACY | SAFETY | ENDOCRINOLOGY & METABOLISM | WEIGHT-LOSS | RANDOMIZED CLINICAL-TRIALS | CHRONIC KIDNEY-DISEASE | BLOOD-PRESSURE | Hypoglycemic Agents - therapeutic use | Age Factors | Double-Blind Method | Humans | Middle Aged | Kaplan-Meier Estimate | Fractures, Bone - epidemiology | Male | Risk | Canagliflozin - adverse effects | Incidence | Dose-Response Relationship, Drug | Cardiovascular Diseases - complications | Canagliflozin - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Accidental Falls | Diabetes Mellitus, Type 2 - complications | Diuretics - adverse effects | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes
by Neal, Bruce and Perkovic, Vlado and de Zeeuw, Dick and Mahaffey, Kenneth W and Fulcher, Greg and Ways, Kirk and Desai, Mehul and Shaw, Wayne and Capuano, George and Alba, Maria and Jiang, Joel and Vercruysse, Frank and Meininger, Gary and Matthews, David and CANVAS Trial Collaborative Grp and CANVAS Trial Collaborative Group
Diabetes Care, ISSN 0149-5992, 03/2015, Volume 38, Issue 3, pp. 403 - 411
OBJECTIVE There are limited data about the effects of sodium-glucose cotransporter 2 inhibitors when used with insulin. We report the efficacy and safety of... 
METFORMIN | GLYCEMIC CONTROL | PLACEBO | MONOTHERAPY | SULFONYLUREA | SITAGLIPTIN | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | RANDOMIZED-TRIAL | POOLED ANALYSIS | MELLITUS | Glycosuria - chemically induced | Hypovolemia - chemically induced | Thiophenes - adverse effects | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Male | Thiophenes - administration & dosage | Weight Loss - drug effects | Dose-Response Relationship, Drug | Glomerular Filtration Rate - drug effects | Hypoglycemic Agents - administration & dosage | Urinary Tract Infections - chemically induced | Female | Blood Pressure - drug effects | Drug Therapy, Combination | Glucosides - adverse effects | Double-Blind Method | Insulin - administration & dosage | Treatment Outcome | Hypoglycemia - drug therapy | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Diabetes Mellitus, Type 2 - physiopathology | Canagliflozin | Glucosides - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Mycoses - chemically induced
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Prescriber beware: report of adverse effect of sodium-glucose cotransporter 2 inhibitor use in a patient with contraindication
by St Hilaire, Reginald, MD and Costello, Heather, MD, MA
American Journal of Emergency Medicine, ISSN 0735-6757, 2014, Volume 33, Issue 4, pp. 604.e3 - 604.e4
Highlights • Euglycemic DKA should be treated aggressively with IV fluids and insulin. • SGL-2 Inhibitors are contraindicated in Type I Diabetes. • Consider... 
Emergency | EMERGENCY MEDICINE | CANAGLIFLOZIN | Reports | Dextrose | Glucose | Hyperglycemia | Emergency medical care | Insulin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
by Wilding, J. P. H and Charpentier, G and Hollander, P and González‐Gálvez, G and Mathieu, C and Vercruysse, F and Usiskin, K and Law, G and Black, S and Canovatchel, W and Meininger, G
International Journal of Clinical Practice, ISSN 1368-5031, 12/2013, Volume 67, Issue 12, pp. 1267 - 1282
AimsCanagliflozin is a sodium glucose co-transporter 2 inhibitor developed for the treatment of type 2 diabetes mellitus (T2DM). This randomised, double-blind,... 
BODY-WEIGHT | MEDICINE, GENERAL & INTERNAL | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | GLYCEMIC CONTROL | PLACEBO | ADD-ON | DAPAGLIFLOZIN | DOUBLE-BLIND | 2 SGLT2 INHIBITOR | IMPROVES INDEXES | BETA-CELL FUNCTION | Thiophenes - adverse effects | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Thiophenes - administration & dosage | Weight Loss - drug effects | Metformin - adverse effects | Dose-Response Relationship, Drug | Young Adult | Hypoglycemic Agents - administration & dosage | Aged, 80 and over | Adult | Female | Blood Pressure - drug effects | Sulfonylurea Compounds - administration & dosage | Metformin - administration & dosage | Glucosides - adverse effects | Insulin-Secreting Cells - physiology | Double-Blind Method | Drug Administration Schedule | Treatment Outcome | Sulfonylurea Compounds - adverse effects | Diabetes Mellitus, Type 2 - blood | Diabetes Mellitus, Type 2 - physiopathology | Canagliflozin | Glucosides - administration & dosage | Adolescent | Lipid Metabolism - drug effects | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Glucose metabolism | Care and treatment | Clinical trials | Hypoglycemic agents | Glucose | Cholesterol | Dextrose | Diabetes therapy | Patient safety | Pharmacology | Diabetes | Drug therapy | Clinical outcomes | Endocrinology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
by Neal, Bruce and Perkovic, Vlado and Mahaffey, Kenneth W and de Zeeuw, Dick and Fulcher, Greg and Erondu, Ngozi and Shaw, Wayne and Law, Gordon and Desai, Mehul and Matthews, David R and CANVAS Program Collaborative Grp and CANVAS Program Collaborative Group
The New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 7, pp. 644 - 657
In this report of two randomized trials, patients with type 2 diabetes at risk for cardiovascular disease received the sodium–glucose cotransporter 2 inhibitor... 
MEDICINE, GENERAL & INTERNAL | METAANALYSIS | ATRIAL-NATRIURETIC-PEPTIDE | RATIONALE | INTENSIVE GLUCOSE CONTROL | PLACEBO-CONTROLLED TRIAL | OUTCOMES | INHIBITORS | STAGE KIDNEY-DISEASE | PROGRESSION | BASE-LINE CHARACTERISTICS | Hypoglycemic Agents - therapeutic use | Albuminuria - complications | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Hospitalization - statistics & numerical data | Kidney Diseases - mortality | Male | Canagliflozin - adverse effects | Disease Progression | Foot - surgery | Glomerular Filtration Rate - drug effects | Diabetes Mellitus, Type 2 - physiopathology | Canagliflozin - therapeutic use | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Aged | Amputation - statistics & numerical data | Kidney Diseases - etiology | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Diabetes Mellitus, Type 2 - complications | Type 2 diabetes | Heart | Complications and side effects | Care and treatment | Abnormalities | Amputation | Myocardial infarction | Heart attacks | Body weight | Clinical trials | Cardiovascular disease | Blood pressure | Drug dosages | Heart failure | Cerebral infarction | Stroke | Statistical analysis | Kidneys | Metatarsal | Diabetes mellitus | Toe | FDA approval | Glomerular filtration rate | Medicine | Studies | Side effects | Sodium | Diabetes | Kidney diseases | Cardiovascular diseases | Health risk assessment | Kidney transplantation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
by Scheen, André J
Drugs, ISSN 0012-6667, 1/2015, Volume 75, Issue 1, pp. 33 - 59
Inhibitors of sodium–glucose co-transporter type 2 (SGLT2) are proposed as a novel approach for the management of type 2 diabetes mellitus (T2DM). Several... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | ADD-ON THERAPY | RANDOMIZED-CONTROLLED-TRIAL | 1ST GLOBAL APPROVAL | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | TOXICOLOGY | PLACEBO-CONTROLLED TRIAL | METFORMIN PLUS SULFONYLUREA | CHRONIC KIDNEY-DISEASE | JAPANESE PATIENTS | INADEQUATE GLYCEMIC CONTROL | BASE-LINE CHARACTERISTICS | Hypoglycemic Agents - therapeutic use | Thiophenes - therapeutic use | Glucosides - pharmacology | Thiophenes - adverse effects | Humans | Thiophenes - pharmacology | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Hypoglycemic Agents - pharmacology | Benzhydryl Compounds - adverse effects | Canagliflozin | Glucosides - therapeutic use | Benzhydryl Compounds - pharmacology | Diabetes Mellitus, Type 2 - drug therapy | Benzhydryl Compounds - therapeutic use | Hypoglycemic Agents - adverse effects | Glucosides - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone
by Forst, T and Guthrie, R and Goldenberg, R and Yee, J and Vijapurkar, U and Meininger, G and Stein, P
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 05/2014, Volume 16, Issue 5, pp. 467 - 477
Aim The efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, was evaluated in patients with type 2 diabetes mellitus (T2DM)... 
thiazolidinediones | metformin | type 2 diabetes | phase 3 study | inhibitor | SGLT2 | Type 2 diabetes | Metformin | Phase 3 study | SGLT2 inhibitor | Thiazolidinediones | GLYCEMIC CONTROL | PLACEBO | ADD-ON | SULFONYLUREA | MONOTHERAPY | SITAGLIPTIN | BODY-WEIGHT | ENDOCRINOLOGY & METABOLISM | COTRANSPORTER 2 INHIBITOR | PANCREATIC-FUNCTION | Thiophenes - therapeutic use | Triazoles - administration & dosage | Thiophenes - adverse effects | Humans | Middle Aged | Pyrazines - administration & dosage | Lipids | Male | Thiophenes - administration & dosage | Genital Diseases, Female - chemically induced | Thiazolidinediones - administration & dosage | Hypoglycemic Agents - administration & dosage | Female | Glucosides - therapeutic use | Blood Pressure - drug effects | Metformin - administration & dosage | Sitagliptin Phosphate | Drug Therapy, Combination | Candidiasis - chemically induced | Glucosides - adverse effects | Hypoglycemic Agents - therapeutic use | Diuretics, Osmotic - adverse effects | Double-Blind Method | Genital Diseases, Male - chemically induced | Treatment Outcome | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Canagliflozin | Glucosides - administration & dosage | Weight Loss | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Glucose metabolism | Care and treatment | Analysis | Low density lipoproteins | Hemoglobin | Glucose | Dextrose | Drug therapy | Diabetes | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights